Linked Comment: Reynolds. Int J Clin Pract 2013; 67: 1214–6.
Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study
Article first published online: 14 AUG 2013
© 2013 Merck Sharp & Dohme Corp. International Journal of Clinical Practice published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
International Journal of Clinical Practice
Volume 67, Issue 12, pages 1228–1237, December 2013
How to Cite
Jameson, K., Amber, V., D'Oca, K., Mills, D., Giles, A. and Ambegaonkar, B. (2013), Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study. International Journal of Clinical Practice, 67: 1228–1237. doi: 10.1111/ijcp.12238
K. Jameson, V. Amber, K. D'Oca and B. Ambegaonkar are all employees of Merck & Co Inc. or its subsidiaries, and hold shares in the company. D. Mills is an independent consultant, and received a restricted grant to carry out all analyses reported in this study. A. Giles has no conflicts of interest.
- Issue published online: 19 NOV 2013
- Article first published online: 14 AUG 2013
- Manuscript Accepted: 22 JUN 2013
- Manuscript Received: 24 APR 2013
- Merck & Co Inc.
- 1British Heart Foundation. Heart statistics. http://www.bhf.org.uk/research/heart-statistics.aspx (accessed 14 November 2012).
- 2European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis., , et al.
- 4General Medical Services – contractural changes 2013/2014. http://www.dh.gov.uk/health/2012/12/gp-contract-proposals/ (accessed 19 February 2013).
- 5British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2): S1–29.
- 7British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. 5): v1–52.
- 8National Institute for Health and Clinical Excellence. NICE Clinical Guideline 67. Lipid Modification: Cardiovascular Risk ASsessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: NICE, 2008.
- 9National Institute for Health and Clinical Excellence. NICE Clinical Guideline 87. Type 2 Diabetes: the Management of Type 2 Diabetes. London: NICE, 2009.
- 31University of Oxford Clinical Trial Service Unit. The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study. http://www.thrivestudy.org/(accessed 24 January 2013).
- 33National Institute for Health and Clinical Excellence. NICE Clinical Guideline 71. Identification and Management of Familial Hypercholesterolaemia. NICE: London, 2008.